NCT05523765

A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis

A Phase 2 Randomized, Double-Masked, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Active Non-Infectious Intermediate-, Posterior-, and Panuveitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Priovant Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).

Conditions

• Non-infectious Intermediate Uveitis
• Non-infectious Posterior Uveitis
• Non-infectious Pan Uveitis

Interventions

Type	Name	Description
DRUG	Brepocitinib	Oral Brepocitinib

Timeline

• Start date: 2022-11-14
• Primary completion: 2024-07-30
• Completion: 2024-07-30
• First posted: 2022-08-31
• Last updated: 2025-07-25

Locations

15 sites across 1 country: United States

Regulatory

• FDA-regulated drug study